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Abstracts A11
anti-hypertensive drug class was assessed in the calendar year (CY) 2000. The time 
to the incidence of dementia was assessed from CY2001 to CY2002. A Multivariable 
Cox regression model adjusted for sociodemographic factors, comorbidities, comedi-
cations and other factors was constructed to estimate the adjusted relative risk of 
dementia associated with use of AHT drug classes. The analysis was stratiﬁ ed for 
patients with and without hypertension. RESULTS: A total 377,838 patients were 
included in the ﬁ nal analysis. The adjusted Hazard Ratios [HRs, (95% CI)] for risk
of dementia with different classes was: Angiotensin receptor blockers (ARB) 0.76
(0.70–0.83), Angiotensin converting enzyme inhibitors (ACEI) 0.89 (0.85–0.93), CCB 
0.93 (0.89–0.97), Diuretics 0.86 (0.83–0.90), Alpha blockers 1.05(1.00–1.09) and 
Beta-Blockers 0.96 (0.92”C1.00). Only ACEI and ARB were signiﬁ cant in a stratiﬁ ed
analysis of patients with HT (ACEI 0.89, 0.85–0.93; ARB 0.78, 0.71–0.85) and 
patients without HT (ACEI 0.81, 0.69–0.94; ARB 0.55 (0.34–0.88). CONCLU-
SIONS: Drugs acting on the Renin-Angiotensin system (RAS) may be protective for 
dementia irrespective of the status of hypertension. More studies are required to
explore this association further.
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OBJECTIVES: Macrovascular disease remains a common and costly comorbidity
in patients with diabetes. The purpose of this study was to examine the marginal 
impact of macrovascular comorbidities on direct and indirect costs associated with 
patients with diabetes in the United States. METHODS: Using the pooled Medical
Expenditure Panel Survey (MEPS) 2003 and 2005 data, a nationally representative 
adult sample (age   18) was included in the study. Direct cost was measured by 
the total health care expenditure. Indirect cost was calculated from the lost produ-
ctivity from missed work days and additional bed days due to illness/injury based on
the 2005 average national hourly wage. The direct costs of both 2003 and 2005 data 
were adjusted to 2005 dollars. Given the heavily right-skewed distribution of the cost 
data, GLM with log-link function and gamma variance was used to identify the rela-
tionship between macrovascular conditions and costs after controlling for age, sex, 
race, ethnicity, education, income, smoking status, health insurance, and number of 
other comorbid categories. Negative binomial models were applied to analyze the 
outcomes of missed work days and bed days. All statistics were adjusted using the
proper sampling weight from the MEPS. RESULTS: The average annual health care
expense for patients with diabetes was $10,909. The average annual missed work days
and additional bed days due to illness/injury for patients with diabetes were 6.3 and 
14.8, respectively, equivalent to $2366 in total. Compared to diabetes patients without 
macrovascular comorbidities (N  3132), those with macrovascular comorbidities
(N  762) had statistically signiﬁ cant higher annual health care expenses ($3587,
p  0.001), more missed work days (4.05, p  0.01) and more bed days (7.15,
p  0.001). The marginal lost productivity cost was $1257 annually. CONCLUSIONS:
Macrovascular comorbidities in patients with diabetes result in increased direct and
indirect costs.
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OBJECTIVES: This study evaluates using Tobit regressions the costs speciﬁ c to each 
type of complication following its onset in annual increments for three years by setting 
(inpatient and outpatient). METHODS: We use a U.S. managed care database to 
identify newly diagnosed type 2 diabetics and then identify the initial onset of 
manifestations of diabetic related complications. Detailed ICD-9 codes associated 
with each type of complication were used to deﬁ ne dichotomous variables as well as 
a time to event variable, one for each selected type of complication. Outpatient and 
inpatients costs were accrued for one, two and three year periods. Because of the
number of zero costs (i.e., not everyone consumes resources such as hospitalization
annually), Tobit regressions were used, a combination of a probit probability model
and a linear regression to resolve the disproportionality in resource utilization. Param-
eter estimates from a Tobit are not directly interpretable as those from a linear regres-
sion and require transformation to obtain the predicted cost values. RESULTS: A total
of 351,900 type 2 diabetics were used in the analyses; 663 patients consumed inpatient
services compared to 226,972 patients consuming outpatient services in year one 
related to a manifestation of a diabetic related complication. For those who encoun-
tered inpatient services, ischemic heart disease ($43,269), congestive heart failure 
($43,870), ketoacidosis ($29,588) and renal manifestations ($24,995) were the most
costly. Outpatient costs for these complications were signiﬁ cantly less, $682, $781, 
$1,031, and $1,267, respectively. Following the onset of these complications addi-
tional costs continued to accrue in year 2, $50,158, $51,669, $35,080 and $28,823,
albeit at a declining rate. The total ﬁ rst year cost across all types of complications was 
$2,827 per person (a 0.00993 ﬁ rst year event rate). CONCLUSIONS: The cost of 
diabetic-related complications is considerable even in the ﬁ rst year of newly diagnosed 
type 2 patients.
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OBJECTIVES: Health technology assessment is used to inform reimbursement deci-
sions for pharmaceuticals globally. The national HTA agencies of the developed world 
have broadly similar methods and use common factors when evaluating technologies 
but sometimes come to different decisions. The aim of this study was to investigate 
the context level and product-related level factors affecting reimbursement decisions
between countries. METHODS: A systematic search was conducted to obtain the
documentation for reimbursement decisions on cancer and cardiovascular medicines. 
Where insufﬁ cient information was published, or reports were not available in English,
decisions were excluded. The analysis was conducted using multinomial logistic regres-
sions and the independent variable included three types of decision: recommended,
recommended for restricted use and not recommended. RESULTS: Detailed informa-
tion was obtained on 194 decisions from Australia, Belgium, Canada, UK, France,
and Sweden. The pooled analysis showed that 27% of medicines were recommended,
41% were recommended for restricted use and 32% were not recommended. The
results demonstrated that several factors were important in producing the different 
types of decision. These included the number of RCTs, publication date, sensitivity
analysis, budget impact, type of medicine and public interest. A sub-analysis for deci-
sions in England showed that the cost per QALY value was statistically signiﬁ cant.
CONCLUSIONS: The results may in part be explained by the different approaches
between countries to conducting economic analysis, differences in cost-effectiveness 
thresholds and variation in the weight given to economic evidence. Further variation
may be explained by factors relating to the country context such as the norms, culture
and policy objectives which inﬂ uence the methods and importance of different product 
level factors included in the HTA. The next stage of the research will investigate these 
factors directly.
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OBJECTIVES: This work describes the development of a framework for health tech-
nology decisions for Ontario Health Technology Advisory Committee (OHTAC) in
Ontario, Canada. The focus of the work is on the development of an explicit frame-
work for the recommendation of adoption of new health technologies. METHODS:
OHTAC convened a “Decision Determinants Sub-Committee” in January 2007 which 
undertook a systematic literature review and conducted key informant interviews to 
develop an explicit decision making framework. The purpose of the literature review 
and key informant interviews was to examine methods and models relevant in our 
setting. The main research questions were the following: a) what criteria are used to
make health technology recommendations?; b) what methods are used to evaluate
health technologies using these criteria (e.g., assigned weights, ranking, rating)?; and 
c) what methodology is used to synthesize these criteria (e.g., process/rules/frame-
works). RESULTS: Given the literature review and views provided by key informants,
the “Decision Determinants Sub-Committee” offered recommendations about decision
criteria, and the process by which decisions are made. Decision criteria include 1)
overall clinical beneﬁ t; 2) consistency with societal and ethical values; 3) value 
for money; and 4) feasibility of adoption into the health system. The sub-committee 
drew on several key ideas: evidence based medicine to reﬂ ect the primacy of scientiﬁ c
evidence, cost-effectiveness analysis to reﬂ ect the importance of using society’s 
resources wisely, and “Accountability for Reasonableness” to describe the elements 
of a fair decision-making process, and a deliberative process to describe how 
separate attributes of health technology ought to be evaluated and weighed. CON-
CLUSIONS: This methodology is currently being pilot tested in a live environment: 
OHTAC. It will be evaluated and revised according to its feasibility, acceptability and
perceived usefulness. The transparency of the process should enable one to have a
clear understanding of how OHTAC arrives at its recommendations regarding speciﬁ c 
technologies.
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OBJECTIVE: Advancement of innovative drugs into commercial development is
increasingly subjected to rigorous internal reviews by manufacturers for minimal 
